Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Mar 3;71(5):1231–1240. doi: 10.1007/s00280-013-2117-x

Fig. 1.

Fig. 1

PBPK-PD model of drug effects on tumor volume progression. The PBPK model is a representative model for everolimus and sorafenib. The dotted lines represent transduction of drug concentrations into inhibition of tumor growth. Symbols are defined in Table 1